Despite a century of cancer research the cause of breast cancer remains unknown. Age, diet, stress, hormone factors, genetic predisposition, and cancer viruses are all suspected as possible causative factors, but totally ignored are infectious bacteria which have been implicated in breast cancer and...
Prior epidemiologic studies have been based largely in white women. In those studies, use ofcombination therapywas associated with anincreased riskofestrogen receptorpositive breast cancer, the most commonly occurring breast cancer subtype, which is known to be sensitive to hormonal factors. Whether pos...
Scientists have discovered a previously unknown mechanism by which estrogen prepares cells to divide, grow and, in the case of estrogen-positive breast cancers, resist cancer drugs. The researchers say the work reveals new targets for breast cancer therapy and will help doctors predict which patients...
Prior to the advent of HER2-targeting therapeutics, patients with HR+/HER2+ breast cancer had significantly worse prognosis compared with HR+/HER2− breast tumors. Clinical trials in the neoadjuvant setting have shown that patients with HR+ tumors have a significantly lower likelihood of achie...
Breast cancer ranks no. 1 in women cancer worldwide, while 60–70% are estrogen receptor alpha positive. The estrogen selective modulators, such as tamoxifen, become the effective drugs for controlling ER alpha breast cancer progression. However, tamoxif
WISP-2 mRNA and protein was overexpressed in preneoplastic and cancerous cells of human breast. Statistical analyses show a significant association between WISP-2 expression and estrogen receptor (ER) positivity. In normal breast, the expression was virtually undetected. The studies showed that WISP-...
Estrogen Receptors as Therapeutic Targets in Breast Cancer The estrogen receptor 伪 (ER伪) has proven to be the single most important target in breast cancer over the last 30 years. The use of the selective ER modu... EA Ariazi,JL Ariazi,F Cordera,... - 《Current Topics》 被引量: 22...
The estrogen receptor (ER) is the single most powerful predictor of breast cancer prognosis as well as an important contributor to the biology of carcinogenesis. In addition, endocrine therapy targeting ER directly (SERMS) or indirectly (aromatase inhibitors) forms the mainstay of adjuant therapy....
breast enlargement (gynecomastia), testicular shrinkage, infertility, sexual dysfunction, and a decrease in muscle mass. It can also lead to mood swings, depression, decreased libido, fatigue, and increased fat storage. High estrogen levels are linked to an increased risk of prostate cancer ...
The cyclin D1-cyclin dependent kinases (CDK)4/6 inhibitor palbociclib in combination with endocrine therapy shows remarkable efficacy in the management of estrogen receptor (ER)-positive and HER2-negative advanced breast cancer (BC). Nevertheless, resistance to palbociclib frequently arises, highlighting...